Alzheimer's drug prescribed off-label could pose risk for some
(University of California - Los Angeles Health Sciences) Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation -- the K-variant of butyrylcholinesterase, or BChE-K -- donezpezil could accelerate cognitive decline. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 24, 2017 Category: Global & Universal Source Type: news
Alzheimer ’s drug prescribed ‘off-label’ for mild cognitive impairment could pose risk for some
FINDINGSDonepezil, a medication that is approved to treat people with Alzheimer ’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation — the K-variant of butyrylcholinesterase, or BChE-K — donezpezil could accelerate cognitiv e decline.BACKGROUNDMild cognitive impairment is a transitional state between normal age-related changes in cognition and dementia. Because many people with the condition display symptoms similar to those caused by Alzheimer’s disease, some phys...
Source: UCLA Newsroom: Health Sciences - February 23, 2017 Category: Universities & Medical Training Source Type: news
Among antidementia drugs, memantine is associated with the highest risk of pneumonia
A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of rivastigmine patches is associated with an increased risk as well. The study found that persons using donepezil or galantamine had the lowest risk of pneumonia. (Source: World Pharma News)
Source: World Pharma News - November 25, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Another Failure In Search For Treatment To Slow Alzheimer ’ s
INDIANAPOLIS (AP) — An experimental treatment for Alzheimer’s failed again in a widely anticipated study, disappointing many who had hoped Eli Lilly had finally found a way to slow the progression of the mind-robbing disease.
The drug did not work better than a placebo treatment in a study of 2,100 people with mild Alzheimer’s, the company announced Wednesday.
“We’re incredibly saddened by the news,” said Maria Carrillo, chief science officer of the Alzheimer’s Association, who was not involved in Lilly’s research. “There was a lot of hope for this avenue, this approach....
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 23, 2016 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Alzheimer's Disease Solanezumab Source Type: news
Aricept (Donepezil Hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 6, 2016 Category: Drugs & Pharmacology Source Type: news
Treatment of Alzheimer ’ s Disease
There is no cure for Alzheimer’s disease and no way to slow the progression of the disease. For some people in the early or middle stages of Alzheimer’s disease, medication such as tacrine (Cognex) may alleviate some cognitive symptoms. Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) may keep some symptoms from becoming worse for a limited time. A fifth drug, memantine (Namenda), has also been approved for use in the United States.
Combining memantine with other Alzheimer’s disease drugs may be more effective than any single therapy. One controlled clinical trial found that patients...
Source: Psych Central - August 17, 2016 Category: Psychiatry Authors: Jane Framingham, Ph.D. Tags: Alzheimer's Medications Memory and Perception Alzheimer's treatment Cognex donepezil Drug Exelon galanta Namenda Reminyl rivastigmine tacrine treatment of alzheimers Source Type: news
donepezil, Aricept, Aricept ODT
Title: donepezil, Aricept, Aricept ODT < br / > Category: Medications < br / > Created: 5/31/1998 12:00:00 AM < br / > Last Editorial Review: 7/29/2016 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - July 29, 2016 Category: Geriatrics Source Type: news
Clinical Trials For New Alzheimer's Medication
Inside Science News Servicenoted on April 16, 2016 that "Alzheimer's is a graveyard for expensive drug tests. One study showed that between 2000 and 2012, 244 compounds were tested in 413 clinical trials. Only one was approved for use, a failure rate of 99.6 percent."
The one medication that was approved since the year 2000, Namzeric, is a medication that combines two previously FDA-approved medications, donepezil and memantine, into one capsule. But neither donepezil nor memantine are medications that effectively treat or significantly improve the lives of most people who take them. Even the third sentence on the N...
Source: Healthy Living - The Huffington Post - July 19, 2016 Category: Consumer Health News Source Type: news
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009).
The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer ' s disease has resulted in a change in the guidance.
Specifically:
donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer ' s disease, and
memantine is now recommended as an option for managing moderate Alzheimer ' s disease for people who cannot take AChE inhibitors, and as an option for managing sev...
Source: Current Awareness Service for Health (CASH) - July 12, 2016 Category: Consumer Health News Source Type: news
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009).
The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease has resulted in a change in the guidance.
Specifically:
donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer's disease, and
memantine is now recommended as an option for managing moderate Alzheimer's disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzhei...
Source: Current Awareness Service for Health (CASH) - July 12, 2016 Category: Consumer Health News Source Type: news
Eisai wins approval to use Aricept for DLB treatment in Philippines
HI-Eisai Pharmaceutical, a subsidiary of Eisai in the Philippines, has obtained approval for a new indication Aricept (donepezil hydrochloride) to treat dementia with Lewy bodies (DLB). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 14, 2016 Category: Pharmaceuticals Source Type: news
Lupin launches generic Aricept tablets in US market
Lupin's product is a generic version of Eisai Inc's Aricept tablets which is indicated for the treatment of dementia of the Alzheimer's type. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 31, 2016 Category: Pharmaceuticals Source Type: news
Characteristics of pediatric exposures to antidementia drugs reported to a poison control system - Thornton SL, Pchelnikova JL, Cantrell FL.
OBJECTIVE: To characterize pediatric exposures to the antidementia drugs donepezil, memantine, rivastigmine, and galantamine by reviewing a poison control system's database. STUDY DESIGN: A retrospective review of a statewide poison control system's databa... (Source: SafetyLit)
Source: SafetyLit - March 11, 2016 Category: Global & Universal Tags: Age: Infants and Children Source Type: news
Alzheimer's Symptomatic Drug Set to Test as Donepezil Combo
BARCELONA — RVT-101, a novel small molecule that increases acetylcholine release, is poised for what its developers say could be its pivotal trial for U.S. approval. (Source: Caring for the Ages)
Source: Caring for the Ages - December 23, 2015 Category: Health Management Authors: Michele G. Sullivan Source Type: news
Revived Alzheimer's Symptomatic Drug Set to Test as Donepezil Combo
BARCELONA — RVT-101, a novel small molecule that increases acetylcholine release, is poised for what its developers say could be its pivotal trial for U.S. approval. (Source: Caring for the Ages)
Source: Caring for the Ages - November 25, 2015 Category: Health Management Authors: Michele G. Sullivan Source Type: news
